Literature DB >> 9223534

Effect of smoking history on [3H]nicotine binding in human postmortem brain.

C R Breese1, M J Marks, J Logel, C E Adams, B Sullivan, A C Collins, S Leonard.   

Abstract

Chronic nicotine administration in animal models evokes a dose-dependent increase in brain nicotinic receptor numbers. Genetically determined variability in nicotinic receptor number in different mouse strains has also been reported, which is thought to affect sensitivity to nicotine, as well as the development of tolerance. Humans self-administer nicotine principally in the form of cigarettes and other tobacco products. The present study compared [3H]nicotine binding in human postmortem brain from thalamus and hippocampus of nonsmoking subjects, subjects who had variable life-long smoking histories and subjects who had quit smoking. A significant increase was seen in [3H]nicotine binding in both hippocampus and thalamus of subjects with life-long smoking histories. In the hippocampus, this change resulted from a change in total receptor number (Bmax), with no change in receptor affinity (Kd). There was also a positive correlation between the degree of smoking, as measured by the average reported packs smoked per day, and the number of nicotine binding sites found in both the hippocampus and thalamus, showing that humans exhibit a dose-dependent increase in brain nicotinic receptor binding. Receptor levels in these brain regions after smoking cessation were at or below those found in the control population, which indicated that smoking-induced changes are reversible after cessation of nicotine treatment. These results suggest that increases in nicotinic receptor levels in the human brain may underlie nicotine tolerance and addiction in smokers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223534

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  129 in total

1.  Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.

Authors:  C P Fenster; T L Whitworth; E B Sheffield; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 2.  Functional genomics and psychiatric illness.

Authors:  Wendy Hasenkamp; Scott E Hemby
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

3.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

Review 4.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

5.  Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms.

Authors:  Christian Luckhaus; Uwe Henning; Stefano Ferrea; Francesco Musso; Arian Mobascher; Georg Winterer
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

6.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

7.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

Review 8.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 9.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

10.  Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons.

Authors:  Raad Nashmi; Mary E Dickinson; Sheri McKinney; Mark Jareb; Cesar Labarca; Scott E Fraser; Henry A Lester
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.